{"id":2334,"date":"2015-10-22T23:08:30","date_gmt":"2015-10-22T21:08:30","guid":{"rendered":"https:\/\/blog.uchceu.es\/farmacia\/?p=2334"},"modified":"2019-11-27T17:33:08","modified_gmt":"2019-11-27T16:33:08","slug":"sera-el-idarucizumab-el-antidoto-frente-al-dabigatran","status":"publish","type":"post","link":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/","title":{"rendered":"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?"},"content":{"rendered":"<p><a href=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-2335\" src=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4-315x262.jpg\" alt=\"Human heart circulation cardiovascular system with anatomy from a healthy body on a background with blood cells as a medical health care symbol of an inner vascular organ as a medical health care concept.\" width=\"428\" height=\"356\" srcset=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4-315x262.jpg 315w, https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg 380w\" sizes=\"auto, (max-width: 428px) 100vw, 428px\" \/><\/a><\/p>\n<p><strong>\u00bfQu\u00e9 es Dabigatran e Idarucizumab?<\/strong><\/p>\n<p><span style=\"text-decoration: underline\">Dabigatran<\/span> es un nuevo anticoagulante oral, inhibidor directo de la trombina.<\/p>\n<p style=\"text-align: left\"><span style=\"text-decoration: underline\">Idarucizumab<\/span>, es un fragmento de anticuerpo monoclonal humano que act\u00faa uni\u00e9ndose al dabigatran y a sus metabolitos con una afinidad 350 veces superior a la que tiene la trombina por el\u00a0dabigatran.<\/p>\n<p style=\"text-align: left\">RE-VERSE AD (Reversal Effects of Idarucizumab on Active Dabigatran), es un estudio prospectivo que tiene como finalidad evaluar la seguridad y eficacia de Idarucizumab para la reversi\u00f3n de dabigatran en:<\/p>\n<ul style=\"text-align: left\">\n<li>Pacientes anticoagulados con dabigatran que, presentan sangrado grave incontrolado. (grupo A)<\/li>\n<li>Pacientes anticoagulados con dabigatran que, necesiten una intervenci\u00f3n quir\u00fargica. (grupo B)<\/li>\n<\/ul>\n<p style=\"text-align: left\"><span style=\"color: #0000ff\">Este estudio tiene como objetivo analizar a 300 pacientes de 38 pa\u00edses diferentes.<\/span><\/p>\n<p style=\"text-align: left\">Recientemente se han publicado los resultados de los 90 primeros pacientes, de los cuales 51 pertenecen al grupo A y 39 al grupo B. Los pacientes recibieron 5 gramos de idarucizumab por v\u00eda intravenosa, repartido en dos bolos de 2.5 gramos separados no m\u00e1s de 15 minutos. La medida principal del estudio ha sido la valoraci\u00f3n farmacodin\u00e1mica para neutralizar la actividad anticoagulante del dabigatran. Los resultados obtenidos han sido muy positivos, ya que la reversi\u00f3n fue del 100% en ambos grupos y se ha demostrado que el idarucizumab neutraliza inmediatamente la actividad del dabigatran (5 Minutos) con un buen perfil de seguridad.<\/p>\n<p style=\"text-align: left\"><strong>Pero\u2026<\/strong><\/p>\n<ol style=\"text-align: left\">\n<li>La ausencia de un grupo control en el estudio observacional, dificulta evaluar el beneficio de idarucizumab en pacientes con sangrado que est\u00e9n tomando dabigatran.<\/li>\n<li>La semivida de dabigatran es corta, por lo que el mejor aliado para revertir la anticoagulaci\u00f3n es el tiempo.<\/li>\n<\/ol>\n<p style=\"text-align: left\">Por lo que idarucizumab quedar\u00e1 reservado para situaciones muy concretas, de uso hospitalario.<\/p>\n<p style=\"text-align: left\">M\u00e1s informaci\u00f3n: Estudio<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00bfQu\u00e9 es Dabigatran e Idarucizumab? Dabigatran es un nuevo anticoagulante oral, inhibidor directo de la trombina. Idarucizumab, es un fragmento de anticuerpo monoclonal humano que act\u00faa uni\u00e9ndose al dabigatran y a sus metabolitos con una afinidad 350 veces superior a la que tiene la trombina por el\u00a0dabigatran. RE-VERSE AD (Reversal Effects of Idarucizumab on Active [&hellip;]<\/p>\n","protected":false},"author":485,"featured_media":2335,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[35,45,47],"class_list":{"0":"post-2334","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-divulgacion-cientifica","8":"tag-farmacologia","9":"tag-investigacion","10":"tag-laboratorio"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?\" \/>\n<meta property=\"og:description\" content=\"\u00bfQu\u00e9 es Dabigatran e Idarucizumab? Dabigatran es un nuevo anticoagulante oral, inhibidor directo de la trombina. Idarucizumab, es un fragmento de anticuerpo monoclonal humano que act\u00faa uni\u00e9ndose al dabigatran y a sus metabolitos con una afinidad 350 veces superior a la que tiene la trombina por el\u00a0dabigatran. RE-VERSE AD (Reversal Effects of Idarucizumab on Active [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog de Farmacia\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FarmaciaUCH\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-22T21:08:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-11-27T16:33:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"380\" \/>\n\t<meta property=\"og:image:height\" content=\"316\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caridad Gimeno Uribes\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caridad Gimeno Uribes\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/\"},\"author\":{\"name\":\"Caridad Gimeno Uribes\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/d6b6fec29da707f1348c0227842f4f6c\"},\"headline\":\"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?\",\"datePublished\":\"2015-10-22T21:08:30+00:00\",\"dateModified\":\"2019-11-27T16:33:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/\"},\"wordCount\":288,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg\",\"keywords\":[\"farmacolog\u00eda\",\"Investigaci\u00f3n\",\"laboratorio\"],\"articleSection\":[\"Divulgaci\u00f3n Cient\u00edfica\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/\",\"name\":\"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?\",\"isPartOf\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg\",\"datePublished\":\"2015-10-22T21:08:30+00:00\",\"dateModified\":\"2019-11-27T16:33:08+00:00\",\"author\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/d6b6fec29da707f1348c0227842f4f6c\"},\"breadcrumb\":{\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#primaryimage\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg\",\"contentUrl\":\"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg\",\"width\":380,\"height\":316,\"caption\":\"Human heart circulation cardiovascular system with anatomy from a healthy body on a background with blood cells as a medical health care symbol of an inner vascular organ as a medical health care concept.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/blog.uchceu.es\/farmacia\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Divulgaci\u00f3n Cient\u00edfica\",\"item\":\"https:\/\/blog.uchceu.es\/farmacia\/category\/divulgacion-cientifica\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#website\",\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/\",\"name\":\"Blog de Farmacia\",\"description\":\"Universidad Cat\u00f3lica y Privada CEU Cardenal Herrera\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/d6b6fec29da707f1348c0227842f4f6c\",\"name\":\"Caridad Gimeno Uribes\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/69754f7c3b11b78a85140e778fa6a5e521bfd19fe7f2b526b70c5a067c3681f4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/69754f7c3b11b78a85140e778fa6a5e521bfd19fe7f2b526b70c5a067c3681f4?s=96&d=mm&r=g\",\"caption\":\"Caridad Gimeno Uribes\"},\"url\":\"https:\/\/blog.uchceu.es\/farmacia\/author\/cgimeno\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/","og_locale":"es_ES","og_type":"article","og_title":"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?","og_description":"\u00bfQu\u00e9 es Dabigatran e Idarucizumab? Dabigatran es un nuevo anticoagulante oral, inhibidor directo de la trombina. Idarucizumab, es un fragmento de anticuerpo monoclonal humano que act\u00faa uni\u00e9ndose al dabigatran y a sus metabolitos con una afinidad 350 veces superior a la que tiene la trombina por el\u00a0dabigatran. RE-VERSE AD (Reversal Effects of Idarucizumab on Active [&hellip;]","og_url":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/","og_site_name":"Blog de Farmacia","article_publisher":"https:\/\/www.facebook.com\/FarmaciaUCH","article_published_time":"2015-10-22T21:08:30+00:00","article_modified_time":"2019-11-27T16:33:08+00:00","og_image":[{"width":380,"height":316,"url":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg","type":"image\/jpeg"}],"author":"Caridad Gimeno Uribes","twitter_misc":{"Escrito por":"Caridad Gimeno Uribes","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#article","isPartOf":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/"},"author":{"name":"Caridad Gimeno Uribes","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/d6b6fec29da707f1348c0227842f4f6c"},"headline":"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?","datePublished":"2015-10-22T21:08:30+00:00","dateModified":"2019-11-27T16:33:08+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/"},"wordCount":288,"commentCount":0,"image":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg","keywords":["farmacolog\u00eda","Investigaci\u00f3n","laboratorio"],"articleSection":["Divulgaci\u00f3n Cient\u00edfica"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/","url":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/","name":"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?","isPartOf":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#primaryimage"},"image":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg","datePublished":"2015-10-22T21:08:30+00:00","dateModified":"2019-11-27T16:33:08+00:00","author":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/d6b6fec29da707f1348c0227842f4f6c"},"breadcrumb":{"@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#primaryimage","url":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg","contentUrl":"https:\/\/blog.uchceu.es\/farmacia\/wp-content\/uploads\/sites\/5\/2015\/10\/anticoagulantes4.jpg","width":380,"height":316,"caption":"Human heart circulation cardiovascular system with anatomy from a healthy body on a background with blood cells as a medical health care symbol of an inner vascular organ as a medical health care concept."},{"@type":"BreadcrumbList","@id":"https:\/\/blog.uchceu.es\/farmacia\/sera-el-idarucizumab-el-antidoto-frente-al-dabigatran\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/blog.uchceu.es\/farmacia\/"},{"@type":"ListItem","position":2,"name":"Divulgaci\u00f3n Cient\u00edfica","item":"https:\/\/blog.uchceu.es\/farmacia\/category\/divulgacion-cientifica\/"},{"@type":"ListItem","position":3,"name":"\u00bfSer\u00e1 el idarucizumab el ant\u00eddoto frente al Dabigatran?"}]},{"@type":"WebSite","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#website","url":"https:\/\/blog.uchceu.es\/farmacia\/en\/","name":"Blog de Farmacia","description":"Universidad Cat\u00f3lica y Privada CEU Cardenal Herrera","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.uchceu.es\/farmacia\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/d6b6fec29da707f1348c0227842f4f6c","name":"Caridad Gimeno Uribes","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/blog.uchceu.es\/farmacia\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/69754f7c3b11b78a85140e778fa6a5e521bfd19fe7f2b526b70c5a067c3681f4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/69754f7c3b11b78a85140e778fa6a5e521bfd19fe7f2b526b70c5a067c3681f4?s=96&d=mm&r=g","caption":"Caridad Gimeno Uribes"},"url":"https:\/\/blog.uchceu.es\/farmacia\/author\/cgimeno\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts\/2334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/users\/485"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/comments?post=2334"}],"version-history":[{"count":0,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/posts\/2334\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/media\/2335"}],"wp:attachment":[{"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/media?parent=2334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/categories?post=2334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.uchceu.es\/farmacia\/wp-json\/wp\/v2\/tags?post=2334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}